Loading...
Please wait, while we are loading the content...
Similar Documents
A Commentary: Effects on Glargine Insulin on Glycemic Control in Patients with Diabetes Mellitus Type II Undergoing Off-pump Coronary Artery Bypass Graft
| Content Provider | Semantic Scholar |
|---|---|
| Author | Nath, Soumya Sankar Das, Pravin Kumar |
| Copyright Year | 2018 |
| Abstract | Insulin glargine (IG) is a long‐acting analogue of human insulin available for clinical use for more than a decade. Evidence from clinical trials suggests that IG has a lower risk of hypoglycemia. Unlike traditional insulin preparations that are absorbed rapidly from the abdomen than from the arm or leg, the site of administration does not influence IG’s unique absorption kinetics, even when the insulin is injected into a working limb.[2] The main role of basal insulin secretion is to limit hepatic glucose production and lipolysis in the fasting state, particularly overnight, without impairing glucose availability for brain function. IG was specifically designed to provide basal insulin requirement.[3] IG lowered plasma glucose by a relatively hepatospecific action with greater suppression of endogenous glucose production compared with little or no increase in glucose disposal.[4] |
| Starting Page | 173 |
| Ending Page | 174 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| PubMed reference number | 29652279 |
| Journal | Medline |
| Volume Number | 21 |
| Alternate Webpage(s) | https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/a7/ACA-21-173.PMC5914218.pdf |
| Alternate Webpage(s) | https://doi.org/10.4103/aca.ACA_213_17 |
| Journal | Annals of cardiac anaesthesia |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
